Hospital Survey Illustrates Drug-Eluting Stent Use Decline In Fourth Quarter
This article was originally published in The Gray Sheet
Executive Summary
U.S. drug-eluting stent utilization rates markedly declined in the fourth quarter of 2006, most significantly in the last month of the year, as doctors chose to use bare-metal stents more frequently due to potential safety risks, a recent survey of about 65 hospitals suggests
You may also be interested in...
Drug-eluting stent penetration
The decline in use of drug-eluting stents in the U.S. reached a new low in the fourth quarter of 2007 - 62% of all stent placements - according to a survey of 75 hospitals by consultant Goodroe Healthcare Solutions. That figure is down from an average of 78% in Q4 of 2006 based on last year's Goodroe survey, and 75% in January (1"The Gray Sheet" Jan. 22, 2007, p. 11). The share of Johnson & Johnson/Cordis' Cypher and Boston Scientific's Taxus DES compared with bare-metal stents has held steady since September, the data shows
Drug-eluting stent penetration
The decline in use of drug-eluting stents in the U.S. reached a new low in the fourth quarter of 2007 - 62% of all stent placements - according to a survey of 75 hospitals by consultant Goodroe Healthcare Solutions. That figure is down from an average of 78% in Q4 of 2006 based on last year's Goodroe survey, and 75% in January (1"The Gray Sheet" Jan. 22, 2007, p. 11). The share of Johnson & Johnson/Cordis' Cypher and Boston Scientific's Taxus DES compared with bare-metal stents has held steady since September, the data shows
NEJM Articles Fuel Debate On Drug-Eluting-Stent Safety
Results of a Swedish registry of almost 20,000 patients, published in the New England Journal of Medicine, are adding fuel to the ongoing debate on drug-eluting-stent safety